Glycogen storage disease type 1a is caused by a deficiency in glucose-6-phosphatase (G6Pase), a nine-helical endoplasmic reticulum transmembrane protein required for maintenance of glucose homeostasis. To date, 75 G6Pase mutations have been identified, including 48 mutations resulting in single-amino acid substitutions. However, only 19 missense mutations have been functionally characterized. Here, we report the results of structure and function studies of the 48 missense mutations and the ⌬F327 codon deletion mutation, grouped as active site, helical, and nonhelical mutations. The 5 active site mutations and 22 of the 31 helical mutations completely abolished G6Pase activity, but only 5 of the 13 nonhelical mutants were devoid of activity. Whereas the active site and nonhelical mutants supported the synthesis of G6Pase protein in a manner similar to that of the wild-type enzyme, immunoblot analysis showed that the majority (64.5%) of helical mutations destabilized G6Pase. Furthermore, we show that degradation of both wild-type and mutant G6Pase is inhibited by lactacystin, a potent proteasome inhibitor. Taken together, we have generated a data base of residual G6Pase activity retained by G6Pase mutants, established the critical roles of transmembrane helices in the stability and activity of this phosphatase, and shown that G6Pase is a substrate for proteasome-mediated degradation.Glycogen storage disease type 1 (GSD-1), 1 also known as von Gierke disease, is a group of autosomal recessive metabolic disorders that occur approximately once in every 100,000 live births (reviewed in Refs. 1-3). GSD-1a (MIM 232 200), the major subtype representing over 80% of GSD-1 cases, is caused by a deficiency in glucose-6-phosphatase (G6Pase; EC 3.1.3.9), which catalyzes the hydrolysis of glucose-6-phosphate to glucose and phosphate, the terminal steps in gluconeogenesis and glycogenolysis. Patients afflicted with GSD-1a cannot maintain glucose homeostasis and manifest hypoglycemia, hepatomegaly, kidney enlargement, growth retardation, hyperlipidemia, hyperuricemia, and lactic acidemia. Long-term complications include gout, hepatic adenomas with risk for malignancy, osteoporosis, platelet dysfunction, pulmonary hypertension, and renal failure.The cloning of the G6Pase gene has enabled researchers to show that GSD-1a individuals are homozygotes or compound heterozygotes for loss of function mutations in the gene (4 -11). To date, 75 G6Pase mutations (including 2 reported here) have been identified in GSD-1a patients on the basis of their absence from the normal population and/or their co-segregation with the disease phenotype (reviewed in Refs. 2 and 3). Interestingly, 48 candidate mutations are missense mutations that result in single-amino acid substitutions. Characterization of these mutations will provide critical information on functionally important residues of the protein. In this study, we functionally characterize all 48 missense mutations by site-directed mutagenesis and transient expression assays. A data base of resi...